USADA announced today that David Clinger, 34, of Murray, Utah, an athlete in the sport of cycling, has accepted a sanction for his second doping offense. This offense is the result of an adverse analytical finding for the anabolic agent, clenbuterol, in an out-of-competition sample collected on June 29, 2011 while Clinger was approaching the end of a two-year period of ineligibility for his first offense, the result of an adverse analytical finding for the presence of testosterone and modafinil in a sample collected in June of 2009. Clinger accepted responsibility for using clenbuterol to enhance his performance. Clenbuterol is a prohibited Anabolic Agent under the USADA Protocol for Olympic and Paralympic Movement Testing and the rules of the International Cycling Union (UCI), both of which have adopted the World Anti-Doping Code and the World Anti-Doping Agency Prohibited List. For this second offense, Clinger received a lifetime period of ineligibility, which began on August 9, 2011.
In an effort to aid athletes, as well as all support team members such as parents and coaches, in understanding the rules applicable to them, USADA provides comprehensive instruction on its website on the testing process and prohibited substances, how to obtain permission to use a necessary medication, and the risks and dangers of taking supplements as well as performance-enhancing and recreational drugs. In addition, the agency manages a drug reference hotline, Drug Reference Online (www.GlobalDRO.com), conducts educational sessions with National Governing Bodies and their athletes, and proactively distributes a multitude of educational materials, such as the Prohibited List, easy-reference wallet cards, periodic newsletters, and protocol and policy reference documentation.
USADA is responsible for the testing and results management process for athletes in the U.S. Olympic and Paralympic Movement, and is equally dedicated to preserving the integrity of sport through research initiatives and educational programs.
For more information or media inquiries, click here.